STOK
Stoke Therapeutics Inc
NASDAQ · Biotechnology
$32.40
+1.92 (+6.30%)
Open$31.70
Previous Close$30.48
Day High$33.48
Day Low$31.06
52W High$38.69
52W Low$5.35
Volume—
Avg Volume584.3K
Market Cap1.85B
P/E Ratio45.08
EPS$0.67
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+54.8% upside
Current
$32.40
$32.40
Target
$50.17
$50.17
$29.72
$50.17 avg
$68.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 38.66M | 323.22M | 315.22M |
| Net Income | -94,100,501 | -37,471,003 | -43,595,472 |
| Profit Margin | -243.4% | -11.6% | -13.8% |
| EBITDA | -105,164,093 | -52,091,948 | -53,358,586 |
| Free Cash Flow | — | -52,998,459 | -42,607,892 |
| Rev Growth | — | +14.4% | -1.8% |
| Debt/Equity | — | 0.58 | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |